PF-08046054 clinical trials
PF-08046054 is named as an intervention in 2 current clinical trials in our UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Canada, Japan, India, Sweden, Denmark, Poland, Czechia, Brazil, Mexico, South Korea, Taiwan, Australia and Israel registers. 2 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Pfizer (1). The most-studied condition is Non-small Cell Carcinoma.
Patient leaflets for PF-08046054
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of PF-08046054
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280 · Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma
|
Phase 3 | Recruiting | Pfizer | UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Czechia, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel |
|
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
NCT05208762 · Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma
|
Phase 1 | Recruiting | Seagen, a wholly owned subsidiary of Pfizer | UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Canada, Japan |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with PF-08046054
7 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Pfizer | 1 |
| Seagen, a wholly owned subsidiary of Pfizer | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about PF-08046054 trials
How many clinical trials are testing PF-08046054?
2 current trials in our UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Canada, Japan, India, Sweden, Denmark, Poland, Czechia, Brazil, Mexico, South Korea, Taiwan, Australia and Israel registers name PF-08046054 (also registered as SGN-PDL1V) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are PF-08046054 trials recruiting patients?
Yes. 2 of the 2 trials are recruiting: 2 with sites in UK, 2 with sites in USA, 2 with sites in China, 2 with sites in Germany, 2 with sites in France, 2 with sites in Spain, 2 with sites in Italy, 2 with sites in Netherlands, 2 with sites in Belgium, 2 with sites in Canada, 2 with sites in Japan, 1 with sites in India, 1 with sites in Sweden, 1 with sites in Denmark, 1 with sites in Poland, 1 with sites in Czechia, 1 with sites in Brazil, 1 with sites in Mexico, 1 with sites in South Korea, 1 with sites in Taiwan, 1 with sites in Australia and 1 with sites in Israel. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors PF-08046054 clinical trials?
Pfizer (1) and Seagen, a wholly owned subsidiary of Pfizer (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how PF-08046054 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how PF-08046054 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists PF-08046054 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.